Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David C Tully

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Bioorganic & Medicinal Chemistry Letters|February 1, 2006
Synthesis and evaluation of arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 3: heterocyclic P3David C Tully, Hong Liu, Phil B Alper, et al.
Bioorganic & Medicinal Chemistry Letters|August 1, 2006
Arylaminoethyl carbamates as a novel series of potent and selective cathepsin S inhibitorsDavid C Tully, Hong Liu, Arnab K Chatterjee, et al.
Bioorganic & Medicinal Chemistry Letters|July 9, 2010
Discovery of novel 1H-imidazol-2-yl-pyrimidine-4,6-diamines as potential antimalarialsXianming Deng, Advait Nagle, Tao Wu, et al.
Bioorganic & Medicinal Chemistry Letters|November 3, 2009
Cell-based optimization of novel benzamides as potential antimalarial leadsTao Wu, Advait Nagle, Tomoyo Sakata, et al.
Journal of Medicinal Chemistry|June 3, 2014
Discovery, optimization, and biological evaluation of 5-(2-(trifluoromethyl)phenyl)indazoles as a novel class of transient receptor potential A1 (TRPA1) antagonistsLisa Rooney, Agnès Vidal, Anne-Marie D'Souza, et al.
Bioorganic & Medicinal Chemistry Letters|August 1, 2006
Synthesis and SAR of arylaminoethyl amides as noncovalent inhibitors of cathepsin S: P3 cyclic ethersDavid C Tully, Hong Liu, Arnab K Chatterjee, et al.
Journal of Medicinal Chemistry|November 18, 2017
Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)David C Tully, Paul V Rucker, Donatella Chianelli, et al.
Antimicrobial Agents and Chemotherapy|December 19, 2025
Identification and characterization of a novel inhibitor of influenza A virus that acts by blocking nucleoprotein oligomerizationVincent H J Leonard, Dianna B Vidales, Benjamin R Taft, et al.
Hepatology Communications|August 8, 2019
Tropifexor-Mediated Abrogation of Steatohepatitis and Fibrosis Is Associated With the Antioxidative Gene Expression Profile in RodentsEloy D Hernandez, Lianxing Zheng, Young Kim, et al.
Journal of Medicinal Chemistry|April 25, 2012
Imidazolopiperazines: lead optimization of the second-generation antimalarial agentsAdvait Nagle, Tao Wu, Kelli Kuhen, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Bioorganic & Medicinal Chemistry Letters|February 1, 2006
Synthesis and evaluation of arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 3: heterocyclic P3David C Tully, Hong Liu, Phil B Alper, et al.
Bioorganic & Medicinal Chemistry Letters|August 1, 2006
Arylaminoethyl carbamates as a novel series of potent and selective cathepsin S inhibitorsDavid C Tully, Hong Liu, Arnab K Chatterjee, et al.
Bioorganic & Medicinal Chemistry Letters|July 9, 2010
Discovery of novel 1H-imidazol-2-yl-pyrimidine-4,6-diamines as potential antimalarialsXianming Deng, Advait Nagle, Tao Wu, et al.
Bioorganic & Medicinal Chemistry Letters|November 3, 2009
Cell-based optimization of novel benzamides as potential antimalarial leadsTao Wu, Advait Nagle, Tomoyo Sakata, et al.
Journal of Medicinal Chemistry|June 3, 2014
Discovery, optimization, and biological evaluation of 5-(2-(trifluoromethyl)phenyl)indazoles as a novel class of transient receptor potential A1 (TRPA1) antagonistsLisa Rooney, Agnès Vidal, Anne-Marie D'Souza, et al.
Bioorganic & Medicinal Chemistry Letters|August 1, 2006
Synthesis and SAR of arylaminoethyl amides as noncovalent inhibitors of cathepsin S: P3 cyclic ethersDavid C Tully, Hong Liu, Arnab K Chatterjee, et al.
Journal of Medicinal Chemistry|November 18, 2017
Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)David C Tully, Paul V Rucker, Donatella Chianelli, et al.
Antimicrobial Agents and Chemotherapy|December 19, 2025
Identification and characterization of a novel inhibitor of influenza A virus that acts by blocking nucleoprotein oligomerizationVincent H J Leonard, Dianna B Vidales, Benjamin R Taft, et al.
Hepatology Communications|August 8, 2019
Tropifexor-Mediated Abrogation of Steatohepatitis and Fibrosis Is Associated With the Antioxidative Gene Expression Profile in RodentsEloy D Hernandez, Lianxing Zheng, Young Kim, et al.
Journal of Medicinal Chemistry|April 25, 2012
Imidazolopiperazines: lead optimization of the second-generation antimalarial agentsAdvait Nagle, Tao Wu, Kelli Kuhen, et al.
Pageof 3